Incidental Findings Found in Whole Genome SNP Microarray Analysis in Both Prenatal and Oncology Studies

2016 ◽  
Vol 209 (5) ◽  
pp. 233-234
Author(s):  
Stuart Schwartz ◽  
Romela Pasion ◽  
Huong Cabral ◽  
Inder Gadi ◽  
Vik Jaswaney ◽  
...  
2018 ◽  
Vol 226-227 ◽  
pp. 53-54
Author(s):  
Alka Chaubey ◽  
Timothy Fee ◽  
Brittany B. Henderson ◽  
Barbara R. DuPont ◽  
Roger E. Stevenson

FEBS Letters ◽  
2007 ◽  
Vol 581 (26) ◽  
pp. 5050-5054 ◽  
Author(s):  
Suvi Asikainen ◽  
Markus Storvik ◽  
Merja Lakso ◽  
Garry Wong

2015 ◽  
Vol 38 (4) ◽  
Author(s):  
Eva C. Winkler ◽  
Christoph Schickhardt

Abstract:The use of whole genome sequencing in translational research not only holds promise for finding new targeted therapies but also raises several ethical and legal questions. The four main ethical and legal challenges are as follows: (1) the handling of additional or incidental findings stemming from whole genome sequencing in research contexts; (2) the compatibility and balancing of data protection and research that is based on broad data sharing; (3) the responsibility of researchers, particularly of non-physician researchers, working in the field of genome sequencing; and (4) the process of informing and asking patients or research subjects for informed consent to the sequencing of their genome. In this paper, first, these four challenges are illustrated and, second, concrete solutions are proposed, as elaborated by the interdisciplinary Heidelberg EURAT project group, as guidelines for the use of genome sequencing in translation research and therapy in Heidelberg.


2014 ◽  
Vol 207 (6) ◽  
pp. 289-290
Author(s):  
A. Yenamandra ◽  
F.C. Wheeler ◽  
A.B. Hollis ◽  
L. Barba ◽  
Y. Wang ◽  
...  

2016 ◽  
Vol 44 (2) ◽  
pp. 292-308 ◽  
Author(s):  
Maya Sabatello ◽  
Paul S. Appelbaum

Whole genome and exome sequencing (WGS/WES) techniques raise hope for a new scale of diagnosis, prevention, and prediction of genetic conditions, and improved care for children. For these hopes to materialize, extensive genomic research with children will be needed. However, the use of WGS/WES in pediatric research settings raises considerable challenges for families, researchers, and policy development. In particular, the possibility that these techniques will generate genetic findings unrelated to the primary goal of sequencing has stirred intense debate about whether, which, how, and when these secondary or incidental findings (SFs) should be returned to parents and minors. The debate is even more pronounced when the subjects are adolescents, for whom decisions about return of SFs may have particular implications. In this paper, we consider the rise of “genomic citizenship” and the main challenges that arise for these stakeholders: adolescents' involvement in decisions relating to return of genomic SFs, the types of SFs that should be offered, privacy protections, and communication between researchers and adolescents about SFs. We argue that adolescents' involvement in genomic SF-related decisions acknowledges their status as valuable stakeholders without detracting from broader familial interests, and promotes more informed genomic citizens.


Sign in / Sign up

Export Citation Format

Share Document